BCG014 / Biocytogen - LARVOL DELTA

BCG014: A CDH3-targeting ADC with a novel TOP1 inhibitor demonstrates robust anti-tumor efficacy in PDX models (AACR 2025) - "Ongoing studies are evaluating the efficacy, pharmacokinetics, and toxicity of BCG014. These findings suggest that BCG014 has the potential to be a novel therapeutic alternative for tumors expressing CDH3."

Clinical • Late-breaking abstract • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH3 • TOP1